Stereotaxis Receives FDA Clearance for Synchrony System Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy STXS?
Source: seekingalpha
- FDA Approval: On Monday, Stereotaxis announced that its Synchrony system received 510(k) clearance from the U.S. FDA, marking a significant advancement in the medical robotics sector and is expected to drive future market share growth.
- Commercial Launch: The system is designed to modernize interventional catheterization labs by integrating display, control, and workflow functions, paired with its cloud-based SynX application to enhance remote connectivity and collaboration, thereby improving healthcare service efficiency.
- Revenue Expectations: Stereotaxis reiterated its expectation to generate over $3 million in revenue this year from Synchrony systems placed independently of its robotic platforms, demonstrating the company's confidence in the market performance of its new product.
- Stock Price Reaction: Following the announcement, Stereotaxis's stock rose 6.95% in pre-market trading to $2.0, reflecting positive market sentiment towards the launch of its new product and investor optimism.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STXS
Wall Street analysts forecast STXS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.880
Low
4.00
Averages
4.20
High
5.00
Current: 1.880
Low
4.00
Averages
4.20
High
5.00
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stereotaxis Receives FDA Clearance for Synchrony System Launch
- FDA Approval: On Monday, Stereotaxis announced that its Synchrony system received 510(k) clearance from the U.S. FDA, marking a significant advancement in the medical robotics sector and is expected to drive future market share growth.
- Commercial Launch: The system is designed to modernize interventional catheterization labs by integrating display, control, and workflow functions, paired with its cloud-based SynX application to enhance remote connectivity and collaboration, thereby improving healthcare service efficiency.
- Revenue Expectations: Stereotaxis reiterated its expectation to generate over $3 million in revenue this year from Synchrony systems placed independently of its robotic platforms, demonstrating the company's confidence in the market performance of its new product.
- Stock Price Reaction: Following the announcement, Stereotaxis's stock rose 6.95% in pre-market trading to $2.0, reflecting positive market sentiment towards the launch of its new product and investor optimism.
See More
Stereotaxis Receives FDA Clearance for Synchrony System
- FDA Milestone: Stereotaxis Inc.'s Synchrony system has received 510(k) clearance from the U.S. FDA, marking a significant milestone in modernizing interventional catheter laboratories, which is expected to enhance the company's market share in surgical robotics.
- Enhanced System Features: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates multiple systems into one intuitive platform, significantly improving visualization and operational efficiency in interventional procedures through custom layouts and streamlined workflows.
- Cloud Connectivity Benefits: The integration with the SynX cloud application enables secure remote collaboration among physicians during operations, enhancing workflow efficiency and patient care quality, thus meeting the high technological demands of modern healthcare.
- Foundation for Future Innovations: Stereotaxis reiterated its guidance of generating over $3 million in revenue this year from Synchrony systems placed independently of robotic systems, emphasizing that this technology will lay the groundwork for future AI applications and remote robotic procedures, driving industry advancement.
See More
Stereotaxis Secures FDA 510(k) Clearance for Synchrony System
- FDA Clearance: Stereotaxis announced that its Synchrony system has received FDA 510(k) clearance, marking a significant advancement in the digitization and modernization of interventional cath labs, which is expected to enhance market competitiveness.
- System Features: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates the viewing and control of all disparate systems in the lab, improving operational efficiency and enhancing the physician's working experience.
- Cloud Application: The system is compatible with the SynX cloud-based application, ensuring compliance with HIPAA and GDPR standards, providing secure remote connectivity, collaboration, recording, and monitoring capabilities, which further enhances operational flexibility in the lab.
- Revenue Outlook: Stereotaxis reiterated its revenue guidance for Synchrony systems, expecting to achieve over $3 million in revenue in the current year, independent of robotic system sales, demonstrating its market potential.
See More
Stereotaxis Receives FDA Clearance for Synchrony System
- FDA Approval: Stereotaxis has received 510(k) clearance from the U.S. FDA for its Synchrony™ system, marking a significant technological advancement in minimally invasive endovascular interventions, which is expected to enhance the company's market share in surgical digital transformation.
- Technological Innovation: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates all lab systems, enhancing the procedural experience and streamlining workflows, which is anticipated to significantly improve operational efficiency for physicians and patient outcomes.
- Future Development: The integration of Synchrony with the SynX™ cloud application offers secure remote connectivity and collaboration capabilities, supporting the introduction of future technologies that enhance clinical insights and automation, potentially creating new revenue streams for the company.
- Market Outlook: Stereotaxis reiterates its guidance of over $3 million in revenue from Synchrony systems this year, reflecting the company's confidence in future growth, particularly in increasingly complex electrophysiology lab environments where the value of technology is becoming more pronounced.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
Stereotaxis Receives FDA Clearance for Synchrony System Launch
- FDA Approval: On Monday, Stereotaxis announced that its Synchrony system received 510(k) clearance from the U.S. FDA, marking a significant advancement in the medical robotics sector and is expected to drive future market share growth.
- Commercial Launch: The system is designed to modernize interventional catheterization labs by integrating display, control, and workflow functions, paired with its cloud-based SynX application to enhance remote connectivity and collaboration, thereby improving healthcare service efficiency.
- Revenue Expectations: Stereotaxis reiterated its expectation to generate over $3 million in revenue this year from Synchrony systems placed independently of its robotic platforms, demonstrating the company's confidence in the market performance of its new product.
- Stock Price Reaction: Following the announcement, Stereotaxis's stock rose 6.95% in pre-market trading to $2.0, reflecting positive market sentiment towards the launch of its new product and investor optimism.
See More
Stereotaxis Receives FDA Clearance for Synchrony System
- FDA Milestone: Stereotaxis Inc.'s Synchrony system has received 510(k) clearance from the U.S. FDA, marking a significant milestone in modernizing interventional catheter laboratories, which is expected to enhance the company's market share in surgical robotics.
- Enhanced System Features: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates multiple systems into one intuitive platform, significantly improving visualization and operational efficiency in interventional procedures through custom layouts and streamlined workflows.
- Cloud Connectivity Benefits: The integration with the SynX cloud application enables secure remote collaboration among physicians during operations, enhancing workflow efficiency and patient care quality, thus meeting the high technological demands of modern healthcare.
- Foundation for Future Innovations: Stereotaxis reiterated its guidance of generating over $3 million in revenue this year from Synchrony systems placed independently of robotic systems, emphasizing that this technology will lay the groundwork for future AI applications and remote robotic procedures, driving industry advancement.
See More
Stereotaxis Secures FDA 510(k) Clearance for Synchrony System
- FDA Clearance: Stereotaxis announced that its Synchrony system has received FDA 510(k) clearance, marking a significant advancement in the digitization and modernization of interventional cath labs, which is expected to enhance market competitiveness.
- System Features: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates the viewing and control of all disparate systems in the lab, improving operational efficiency and enhancing the physician's working experience.
- Cloud Application: The system is compatible with the SynX cloud-based application, ensuring compliance with HIPAA and GDPR standards, providing secure remote connectivity, collaboration, recording, and monitoring capabilities, which further enhances operational flexibility in the lab.
- Revenue Outlook: Stereotaxis reiterated its revenue guidance for Synchrony systems, expecting to achieve over $3 million in revenue in the current year, independent of robotic system sales, demonstrating its market potential.
See More
Stereotaxis Receives FDA Clearance for Synchrony System
- FDA Approval: Stereotaxis has received 510(k) clearance from the U.S. FDA for its Synchrony™ system, marking a significant technological advancement in minimally invasive endovascular interventions, which is expected to enhance the company's market share in surgical digital transformation.
- Technological Innovation: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates all lab systems, enhancing the procedural experience and streamlining workflows, which is anticipated to significantly improve operational efficiency for physicians and patient outcomes.
- Future Development: The integration of Synchrony with the SynX™ cloud application offers secure remote connectivity and collaboration capabilities, supporting the introduction of future technologies that enhance clinical insights and automation, potentially creating new revenue streams for the company.
- Market Outlook: Stereotaxis reiterates its guidance of over $3 million in revenue from Synchrony systems this year, reflecting the company's confidence in future growth, particularly in increasingly complex electrophysiology lab environments where the value of technology is becoming more pronounced.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
